+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Immunotherapy Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797976
The global cancer immunotherapy market size attained a value of USD 106.6 billion in 2022. The market is likely to grow at a CAGR of 11.60% during the forecast period of 2023-2031 to attain a value of USD 284.7 billion by 2031.

Cancer Immunotherapy Market: Introduction

Cancer immunotherapy is a type of cancer treatment that harnesses the power of the immune system to fight cancer. The immune system is the body's natural defence mechanism against foreign invaders, such as viruses and bacteria, and against abnormal cells, including cancer cells. Cancer immunotherapy works by boosting or directing the immune system to recognize and attack cancer cells more effectively.

There are several types of cancer immunotherapy, including:
  • Checkpoint inhibitors: These drugs block the molecules that cancer cells use to evade the immune system, allowing the immune system to recognize and attack the cancer cells
  • CAR T-cell therapy: This involves removing T-cells from a patient's blood, modifying them in a lab to target cancer cells, and then infusing them back into the patient's bloodstream
  • Cancer vaccines: These vaccines are designed to stimulate the immune system to recognize and attack cancer cells
  • Immune system modulators: These drugs are designed to boost the overall activity of the immune system
The benefits of cancer immunotherapy are many. Compared to traditional cancer treatments such as chemotherapy and radiation, immunotherapy tends to have fewer side effects and can be more targeted. In some cases, immunotherapy can even result in long-lasting remissions and cures. Immunotherapy is also being studied in the treatment of parasitic infections, such as malaria, by targeting specific molecules on the parasite's surface to trigger an immune response.

Cancer Immunotherapy Market Segmentations

The market can be categorised into therapy type, application, distribution channels, end use, and regions.

Market Breakup by Therapy Type

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Immunomodulators
  • Immune Check Point Inhibitors
  • Others

Market Breakup by Application

  • Prostate Cancer
  • Breast Cancer
  • Skin Cancer
  • Lung Cancer
  • Melanoma
  • Others

Market Breakup by Distribution Channels

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by End Use

  • Hospitals and Clinics
  • Cancer Research Centres

Cancer Immunotherapy Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Cancer Immunotherapy Market Scenario

The growth of the cancer immunotherapy market can be attributed to several factors. First, there is a growing incidence of cancer worldwide, which is driving the demand for effective and innovative cancer treatments. Second, the development of new immunotherapies, such as checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, is fuelling the growth of the market. Third, there is a significant investment in research and development activities in the field of cancer immunotherapy, which is resulting in the discovery of new targets and therapies.

North America is the largest market for cancer immunotherapy, followed by Europe and Asia Pacific. The high prevalence of cancer in North America, coupled with the availability of advanced healthcare infrastructure, is driving the growth of the market in the region. In Europe, the market growth is driven by the increasing government funding for cancer research and the development of novel immunotherapies. In Asia Pacific, the market is growing rapidly due to the rising incidence of cancer, the increasing adoption of immunotherapies, and the presence of a large patient pool.

However, the high cost of cancer immunotherapy is a major barrier to market growth. Many of the newer immunotherapies are expensive, which limits their adoption in low- and middle-income countries. In addition, the high cost of development and regulatory hurdles are also limiting the number of players entering the market.

Overall, the cancer immunotherapy market is poised for continued growth in the coming years, driven by factors such as the increasing incidence of cancer, the development of new immunotherapies, and the rising investment in research and development activities. However, addressing the high cost of immunotherapy and improving access to these treatments in low- and middle-income countries will be key to ensuring the market's sustained growth.

Key Players in the Global Cancer Immunotherapy Market

The report gives an in-depth analysis of the key players involved in the cancer immunotherapy market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc
  • Astellas Pharma Inc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Genentech, Inc (Roche)
  • Lilly
  • Johnson & Johnson Services, Inc
  • Immunocore, Ltd
  • Merck

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Immunotherapy Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Epidemiology (2016-2031)
5.3 Europe Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
5.5 Latin America Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
6 Global Cancer Immunotherapy Market Overview
6.1 Global Cancer Immunotherapy Market Historical Value (2016-2022)
6.2 Global Cancer Immunotherapy Market Forecast Value (2023-2031)
7 Global Cancer Immunotherapy Market Landscape
7.1 Global Cancer Immunotherapy Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Cancer Immunotherapy Product Landscape
7.2.1 Analysis by Therapy Type
7.2.2 Analysis by End User
7.2.3 Analysis by Applications
8 Cancer Immunotherapy Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Cancer Immunotherapy Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Cancer Immunotherapy Market Segmentation
11.1 Global Cancer Immunotherapy Market by Therapy Type
11.1.1 Market Overview
11.1.2 Monoclonal Antibodies
11.1.3 Cancer Vaccines
11.1.4 Immunomodulators
11.1.5 Immune Check Point Inhibitors
11.1.6 Others
11.2 Global Cancer Immunotherapy Market by Application
11.2.1 Market Overview
11.2.2 Prostate Cancer
11.2.3 Breast Cancer
11.2.4 Skin Cancer
11.2.5 Lung Cancer
11.2.6 Melanoma
11.2.7 Others
11.3 Global Cancer Immunotherapy Market by Distribution Channels
11.3.1 Market Overview
11.3.2 Hospitals Pharmacy
11.3.3 Retail Pharmacy
11.3.4 Online Pharmacy
11.3.5 Others
11.4 Global Cancer Immunotherapy Market by End Use
11.4.1 Market Overview
11.4.2 Hospitals & Clinics
11.4.3 Cancer Research Centers
11.5 Global Cancer Immunotherapy Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Cancer Immunotherapy Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Cancer Immunotherapy Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Cancer Immunotherapy Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Cancer Immunotherapy Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Cancer Immunotherapy Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 AstraZeneca
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 F. Hoffmann-La Roche Ltd
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Amgen Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Astellas Pharma Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Bayer AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Bristol-Myers Squibb Company
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Genentech, Inc (Roche)
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Lilly
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Johnson & Johnson Services, Inc
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Immunocore, Ltd
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Merck
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Global Cancer Immunotherapy Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Astrazeneca
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Genentech, Inc (Roche)
  • Lilly
  • Johnson & Johnson Services, Inc
  • Immunocore, Ltd
  • Merck

Methodology

Loading
LOADING...

Table Information